

# LOBBYING REPORT

DATE: 11/1/99 PH 1:26

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

H.D.

1. Registrant Name Skadden, Arps, Slate, Meagher & Flom LLP			
2. Address <input type="checkbox"/> Check if different than previously reported 1440 New York Avenue, N.W. Washington, D.C. 20005			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country): _____			
4. Contact Name James A. Losey	Telephone (202) 371-7000	E-mail (optional)	5. Senate ID # 35560-191
7. Client Name <input type="checkbox"/> Self Glaxo Wellcome, Inc.	6. House ID # 31706025		

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☒

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ -> Termination Date \_\_\_\_\_

11. No Lobbying Activity ☐

<b>INCOME OR EXPENSES - Complete Either Line 12 OR Line 13</b>	
<b>12. Lobbying Firms</b>  INCOME relating to lobbying activities for this reporting period was:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input checked="" type="checkbox"/> -> \$ <u>20,000</u> Income (nearest \$20,000)  Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>13. Organizations</b>  EXPENSES relating to lobbying activities for this reporting period were:  Less than \$10,000 <input type="checkbox"/>  \$10,000 or more <input type="checkbox"/> -> \$ _____ Expenses (nearest \$20,000)  <b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.  <input type="checkbox"/> Method A. Reporting amounts using LDA definitions only  <input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  <input type="checkbox"/> Method C. Reporting amounts under section 162(c) of the Internal Revenue Code

Signature \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Registrant Name Skadden, Arps Client Name Glaxo Wellcome, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCB (one per page)

16. Specific lobbying issues

Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the metered-dose inhalers, as well as national regulatory actions regarding same.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives  
U.S. Senate  
Environmental Protection Agency  
Department of State  
Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
James A. Losey, Partner		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patients and physician access to essential medical treatment options.

Signature \_\_\_\_\_ Date \_\_\_\_\_

Printed Name and Title \_\_\_\_\_

Registrant Name Skadden, Arps Client Name Glaxo Wellcome, Inc.

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page)

16. Specific lobbying issues

Efforts regarding U.S. government position on the Montreal Protocol "transition strategy" for the metered-dose inhalers, as well as national regulatory actions regarding same issue.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

U.S. House of Representatives  
U.S. Senate  
Environmental Protection Agency  
Department of State  
Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	Now
James A. Losey, Partner		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☐ Check if None

Glaxo Wellcome, Inc. owned by Glaxo Wellcome, PLC, sells pharmaceutical products in the U.S. and abroad and seeks to ensure transition policy for MDIs that protect patient and physician access to essential medical treatment options.

Signature James A. Losey Date 2/10/00

Printed Name and Title James A. Losey, Partner